

Stockholm, 28 September 2012

New number of shares and votes in Swedish Orphan Biovitrum AB (publ)

The total number of shares in Swedish Orphan Biovitrum AB (publ) as per 28 September 2012 amounts to 269,634,858 shares, whereof 265,226,598 common shares and 4,408,260 class C shares, corresponding to in total 265,667,424 votes.

The increase in the number of shares and votes results from an issue of 1,655,136 class C shares under Swedish Orphan Biovitrum's incentive program. The class C shares are intended to ensure fulfillment of commitments under incentive programs. All 4,408,260 class C shares are held by the company.

For further information, please contact:

Åsa Stenqvist, Head of Communications and Investor Relations (Interim)

Tel.: +46 8 697 21 88

About Swedish Orphan Biovitrum (Sobi)

Sobi is an international healthcare company dedicated to bringing innovative therapies and services to improve the lives of rare disease patients. The product portfolio is primarily focused on inflammation and genetic diseases, with three late stage biological development projects within hemophilia and neonatology. Sobi also markets more than 40 products for companies in the specialty and rare disease space. In 2011, Sobi had revenues of SEK 1.9 billion and around 500 employees. The share (STO: SOBI) is listed on NASDAQ OMX Stockholm. More information is available at www.sobi.com.

The information above has been published pursuant to the Swedish Securities Market Act and/or the Financial Instruments Trading Act. The information was released for public distribution on 28 September 2012 at 15.45 p.m. CET.